UY35370A - Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 - Google Patents
Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4Info
- Publication number
- UY35370A UY35370A UY0001035370A UY35370A UY35370A UY 35370 A UY35370 A UY 35370A UY 0001035370 A UY0001035370 A UY 0001035370A UY 35370 A UY35370 A UY 35370A UY 35370 A UY35370 A UY 35370A
- Authority
- UY
- Uruguay
- Prior art keywords
- benzoimidazol
- receptor
- histamine
- modulators
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Benzoimidazol-2-il pirimidinas, métodos de purifi cación de estas, y composiciones farmacéuticas y métodos para el tratamiento de estados patológicos , trastornos y afecciones mediados por la activid ad del receptor H4 que incluyen alergia, asma, en fermedades autoinmunes y prurito.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361773706P | 2013-03-06 | 2013-03-06 | |
US201361776260P | 2013-03-11 | 2013-03-11 | |
US201361784909P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35370A true UY35370A (es) | 2014-09-30 |
Family
ID=51488591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035370A UY35370A (es) | 2013-03-06 | 2014-03-06 | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
Country Status (38)
Country | Link |
---|---|
US (4) | US8859575B2 (es) |
EP (2) | EP3660011A1 (es) |
JP (1) | JP6471103B2 (es) |
KR (1) | KR102230383B1 (es) |
CN (1) | CN105025898B (es) |
AU (1) | AU2014225675B2 (es) |
BR (1) | BR112015021463A8 (es) |
CA (1) | CA2903737C (es) |
CL (1) | CL2015002434A1 (es) |
CR (1) | CR20150435A (es) |
CY (1) | CY1122545T1 (es) |
DK (1) | DK2964229T3 (es) |
DO (1) | DOP2016000027A (es) |
EA (1) | EA201591648A1 (es) |
ES (1) | ES2773543T3 (es) |
GT (1) | GT201500243A (es) |
HK (1) | HK1218513A1 (es) |
HR (1) | HRP20200253T1 (es) |
HU (1) | HUE047681T2 (es) |
IL (1) | IL240247B (es) |
JO (1) | JO3516B1 (es) |
LT (1) | LT2964229T (es) |
MX (1) | MX2015011688A (es) |
MY (1) | MY180726A (es) |
NZ (1) | NZ710640A (es) |
PE (1) | PE20151536A1 (es) |
PH (1) | PH12015501731A1 (es) |
PL (1) | PL2964229T3 (es) |
PT (1) | PT2964229T (es) |
RS (1) | RS59909B1 (es) |
SA (1) | SA515360981B1 (es) |
SG (1) | SG11201507117XA (es) |
SI (1) | SI2964229T1 (es) |
TW (1) | TWI617554B (es) |
UA (1) | UA118754C2 (es) |
UY (1) | UY35370A (es) |
WO (1) | WO2014138368A1 (es) |
ZA (1) | ZA201507351B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA016264B1 (ru) | 2006-03-31 | 2012-03-30 | Янссен Фармацевтика Н.В. | Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
UY35370A (es) | 2013-03-06 | 2014-09-30 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
US9096596B2 (en) | 2013-03-14 | 2015-08-04 | Janssen Pharmaceutica Nv | P2X7 modulators |
JP6592510B2 (ja) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節因子 |
AU2017394032B8 (en) | 2017-01-21 | 2020-10-22 | Guangzhou Hanfang Pharmaceutical Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
EP4038070A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Pharmaceutica NV | Radiolabelled mgl pet ligands |
KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
US4191828A (en) | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
US4190601A (en) | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | 2−アミノ−5−シアノピリミジンの製法 |
GB9410031D0 (en) | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036898A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
JP2000507591A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU5495798A (en) | 1997-01-16 | 1998-08-07 | Sekisui Chemical Co., Ltd. | External preparations for percutaneous absorption |
JP2001509176A (ja) | 1997-01-17 | 2001-07-10 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
WO1998044797A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US6399612B1 (en) | 1997-10-06 | 2002-06-04 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
DE69919707T2 (de) | 1998-06-19 | 2005-09-01 | Chiron Corp., Emeryville | Glycogen synthase kinase 3 inhibitoren |
PT1038875E (pt) * | 1999-03-25 | 2003-10-31 | Synthon Bv | Derivados de imidazopiridina e processo para os preparar |
KR100718830B1 (ko) | 1999-06-23 | 2007-05-17 | 사노피-아벤티스 도이칠란트 게엠베하 | 치환된 벤즈이미다졸 및 이의 제조방법 |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
HUP0202678A3 (en) | 1999-09-30 | 2004-06-28 | Pfizer | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use |
ID30204A (id) | 1999-12-27 | 2001-11-15 | Japan Tobacco Inc | Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
PT1475093E (pt) | 2000-04-24 | 2006-11-30 | Teva Pharma | Hemitartarato de zolpidem micronizado |
RU2002131589A (ru) * | 2000-04-24 | 2004-03-27 | Тева Фамэситикл Индастрис Лтд. (Il) | Гемитартрат золпидема |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
EP1305401A2 (en) | 2000-06-28 | 2003-05-02 | Thromb-X N.V. | Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals |
AU2001289701B2 (en) | 2000-07-21 | 2004-06-24 | Syngenta Participations Ag | Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine |
AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
US6624180B2 (en) | 2000-11-20 | 2003-09-23 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
JP2004525139A (ja) | 2001-03-23 | 2004-08-19 | 中外製薬株式会社 | Flt−1リガンド、および血管形成により調節可能な疾患の治療におけるそれらの使用 |
US20050107400A1 (en) | 2001-03-30 | 2005-05-19 | Boyd Leslie F. | Use of pyrazolopyridines as therapeutic compounds |
EP1408986B1 (en) | 2001-05-08 | 2008-09-24 | Yale University | Proteomimetic compounds and methods |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
DE60213841T2 (de) | 2001-11-05 | 2007-02-15 | Merck Patent Gmbh | Hydrazono-malonitrile |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US7148236B2 (en) | 2002-01-17 | 2006-12-12 | Merck & Co., Inc. | Modulators of acetylcholine receptors |
TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
US7498349B2 (en) | 2002-08-02 | 2009-03-03 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
EP1543011B1 (en) | 2002-09-06 | 2006-05-03 | Janssen Pharmaceutica N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
CN1694703A (zh) | 2002-09-06 | 2005-11-09 | 詹森药业有限公司 | 吲哚基衍生物在制备治疗变应性鼻炎的药物中的用途 |
US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
RU2005106274A (ru) | 2002-09-06 | 2005-11-10 | Янссен Фармацевтика, Н.В. (Be) | Гетероциклические соединения |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040105856A1 (en) | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
EP1622910A1 (en) | 2003-05-05 | 2006-02-08 | F. Hoffmann-La Roche Ag | Fused pyrimidine derivatives with crf activity |
BRPI0410348A (pt) | 2003-05-14 | 2006-05-30 | Torreypines Therapeutics Inc | compostos e usos dos mesmos na modulação de amilóide-beta |
SE0302116D0 (sv) * | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
JP2007502300A (ja) | 2003-08-13 | 2007-02-08 | カイロン コーポレイション | Gsk−3インヒビターおよびその使用 |
JP5042626B2 (ja) | 2003-09-22 | 2012-10-03 | エス*バイオ プライベート リミティッド | ベンズイミダゾール誘導体:製造及び医薬適用 |
JP2007507514A (ja) | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
US7432378B2 (en) | 2003-09-30 | 2008-10-07 | Janssen Pharmaceutica, N.V. | Benzoimidazole compounds |
US7115646B2 (en) | 2003-10-08 | 2006-10-03 | Bristol Myers Squibb, Co. | Cyclic diamines and derivatives as factor Xa inhibitors |
WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
KR101217103B1 (ko) | 2004-03-25 | 2012-12-31 | 얀센 파마슈티카 엔.브이. | 이미다졸 화합물 |
US7960394B2 (en) | 2004-05-31 | 2011-06-14 | Banyu Pharmaceutical Co., Ltd. | Quinazoline derivative |
ES2362102T3 (es) | 2004-06-30 | 2011-06-28 | Janssen Pharmaceutica Nv | Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer. |
JP4972804B2 (ja) | 2004-08-31 | 2012-07-11 | Msd株式会社 | 新規置換イミダゾール誘導体 |
WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
AU2005316091B2 (en) | 2004-12-17 | 2011-12-01 | Merck Canada Inc. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
EP1863756A1 (en) | 2005-03-24 | 2007-12-12 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
CN103110635A (zh) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
JP2009507896A (ja) | 2005-09-13 | 2009-02-26 | パラウ・フアルマ・ソシエダツド・アノニマ | ヒスタミンh4受容体活性の調節剤としての2−アミノピリミジン誘導体 |
AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
ATE533485T1 (de) | 2005-10-31 | 2011-12-15 | Merck Sharp & Dohme | Cetp-inhibitoren |
US20090182142A1 (en) | 2005-12-02 | 2009-07-16 | Shigeru Furukubo | Aromatic Compound |
CA2643562A1 (en) | 2006-02-24 | 2007-08-30 | Anh Chau | 2-(phenyl or heterocyclic)-1h-phenanthro[9,10-d]imidazoles |
EA016264B1 (ru) | 2006-03-31 | 2012-03-30 | Янссен Фармацевтика Н.В. | Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н |
ES2349237T3 (es) | 2006-03-31 | 2010-12-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidinas como moduladores del receptor de histamina h4. |
CN101472584B (zh) | 2006-04-07 | 2013-04-24 | 詹森药业有限公司 | 用作组胺h4受体调节剂的吲哚类和苯并咪唑类 |
US20090069343A1 (en) | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
US20090192158A1 (en) | 2006-05-02 | 2009-07-30 | Stacia Kargman | Methods for Treating or Preventing Neoplasias |
AU2007252249A1 (en) | 2006-05-18 | 2007-11-29 | Merck Frosst Canada Ltd. | Phenanthrene derivatives as mPGES-1 inhibitors |
TW200821315A (en) | 2006-07-11 | 2008-05-16 | Janssen Pharmaceutica Nv | Benzofuro-and benzothienopyrimidine modulators of the histamine H4 receptor |
US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
NZ589531A (en) | 2008-06-12 | 2012-08-31 | Janssen Pharmaceutica Nv | Use of histamine H4 antagonist for the treatment of post-operative tissue adhesions after surgical procedures |
CA2727684C (en) | 2008-06-12 | 2017-01-31 | Janssen Pharmaceutica Nv | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor |
CN102137857A (zh) | 2008-06-30 | 2011-07-27 | 詹森药业有限公司 | 用于制备苯并咪唑-2-基嘧啶衍生物的方法 |
ES2538135T3 (es) | 2008-06-30 | 2015-06-17 | Janssen Pharmaceutica N.V. | Proceso para la preparación de derivados sustituidos de pirimidina |
WO2010025314A2 (en) * | 2008-08-28 | 2010-03-04 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
IT1395963B1 (it) * | 2009-06-04 | 2012-11-02 | Rottapharm Spa | Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali |
TWI519533B (zh) | 2010-11-01 | 2016-02-01 | Lg生命科學有限公司 | 1-{(2S)-2-胺基-4-[2,4-雙(三氟甲基)-5,8-二氫吡啶并[3,4-d]嘧啶-7(6H)-基]-4-側氧丁基}-5,5-二氟哌啶-2-酮酒石酸鹽之水合物 |
EP2465498A1 (en) * | 2010-11-23 | 2012-06-20 | Faes Farma, S.A. | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions |
UY35370A (es) | 2013-03-06 | 2014-09-30 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
-
2014
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 MX MX2015011688A patent/MX2015011688A/es active IP Right Grant
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en active Application Filing
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko active IP Right Grant
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731A1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
-
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en active Active
- 2016-06-07 HK HK16106550.1A patent/HK1218513A1/zh unknown
- 2016-08-03 US US15/227,878 patent/US9663497B2/en active Active
-
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown
- 2020-02-14 HR HRP20200253TT patent/HRP20200253T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35370A (es) | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 | |
UY30253A1 (es) | Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina | |
DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
ECSP099582A (es) | Moduladores 2-aminopirimidina del receptor de histamina h4 | |
CO6321192A2 (es) | Moduladores de diamino-piridina pirimidina y piridazina del receptor h4 de histamina | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
SG10201806849WA (en) | Cyclopropylamines as lsd1 inhibitors | |
CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
UY30479A1 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4 | |
UY37018A (es) | Inhibidores bicíclicos de pad4 | |
TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
DOP2015000290A (es) | Benzoxazoles sustituidos | |
EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
EA201590349A1 (ru) | Режимы лечения | |
AR095033A1 (es) | Moduladores benzoimidazol-2-il pirimidina modulares del receptor de histamina h₄ | |
CU20140102A7 (es) | Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks | |
EA201691620A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. |